See today's BioWorld Asia
To read the full story, subscribe or sign in.

APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses

Feb. 18, 2025
By Marian (YoonJee) Chu
Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, under undisclosed terms Feb. 11.
BioWorld Asia Deals and M&A Cancer Endocrine/metabolic Inflammatory Antibody Antibody-drug conjugate Biosimilar Monoclonal antibody Asia-Pacific Europe Australia China U.S.